Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for joining us and welcome to the Innate Farmer third quarter 2025 business update and financial results. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please raise your hand. If you have dialled into today's call, please press star nine to raise your hand and star six to unmute. I will now hand the conference over to Stephanie Cornyn, Vice President, Investor Relations, Communication and Commercial Strategy at N8 Pharma. Please go ahead. Good morning and good afternoon everyone. Thank you for joining us for INET Pharma Q3 2025 Business Update and Financial Results Conference Call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I'd like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. To begin, I briefly cover today's agenda. Our CEO, Jonathan Dickinson, will discuss our strategic priorities and pass forward. Then our CMO, Sonia Quarantino, will present clinical pipeline updates on IPH4502, Monalizumab, and Lacutamab. Afterward, I will present the commercial opportunity for Lacutamab before turning back to Jonathan with closing remarks and will open for the call for Q&A. With that, I'll now hand it over to Jonathan. Thank you, Stephanie. Good morning to those joining from the U.S. and good afternoon to our European audience. Turning to slide five, I would like to start with the strong momentum around LakutaMap, supported by meaningful regulatory progress and new commercial opportunity insights. A few days ago, we received FDA clearance to ini...